122 related articles for article (PubMed ID: 2834481)
1. [Is enoxaparine (PK 10169) a good anticoagulant in chronic hemodialysis?].
Briquel ME; Kessler M; André E; Huu TC; Alexandre P; Renoult E; Jonon B
J Mal Vasc; 1987; 12 Suppl B():111-3. PubMed ID: 2834481
[TBL] [Abstract][Full Text] [Related]
2. [Anticoagulation in hemodialysis sessions with a low molecular weight heparin (CY 222, Choay). Dosage studies in chronic hemodialysis. Its use in patients at high risk of hemorrhage].
Dieval J; Morinière P; Roussel B; Bayrou B; Fournier A; Delobel J
J Mal Vasc; 1987; 12 Suppl B():114-8. PubMed ID: 2834482
[TBL] [Abstract][Full Text] [Related]
3. [Use in hemodialysis and hemofiltration of CY 216 (Fraxiparine) administered via intravenous bolus in patients with acute and chronic renal insufficiency with and without hemorrhagic risk].
Steinbach G; Bosc C; Caraman PL; Azoulay E; Olry L; D'Azemar P; Chopin J
Nephrologie; 1990; 11(1):17-21. PubMed ID: 2165223
[TBL] [Abstract][Full Text] [Related]
4. Comparison of two low-molecular weight heparins (LMWHs), tinzaparin and bemiparin, during hemodialysis.
Christidou FN; Frangia TK; Bamichas GI; Gionanlis LC; Natse TA; Georgoulis IE; Sombolos KI
Int J Clin Pharmacol Ther; 2005 Jul; 43(7):335-8. PubMed ID: 16035376
[TBL] [Abstract][Full Text] [Related]
5. [Biological activity of enoxaprine (PK 10169) in hemodialysis. A dose study].
Pouzol P; Polack B; Dechelette E; Jurkovitz C; Cusin E
J Mal Vasc; 1987; 12 Suppl B():108-10. PubMed ID: 2834480
[TBL] [Abstract][Full Text] [Related]
6. Low molecular weight heparin (CY-216) versus unfractionated heparin in chronic hemodialysis.
Grau E; Sigüenza F; Maduell F; Linares M; Olaso MA; Martinez R; Caridad A
Nephron; 1992; 62(1):13-7. PubMed ID: 1331831
[TBL] [Abstract][Full Text] [Related]
7. [The use of enoxaparine for anticoagulation in extracorporeal circulation in hemodialysis at high risk for hemorrhage].
Dechelette E; Pouzol P; Jurkovitz C; Kuentz F; Polack B; Cuzin E; Woler M
J Mal Vasc; 1987; 12 Suppl B():105-7. PubMed ID: 2834479
[TBL] [Abstract][Full Text] [Related]
8. Intravenous and subcutaneous weight-based dosing of the low molecular weight heparin tinzaparin (Innohep) in end-stage renal disease patients undergoing chronic hemodialysis.
Hainer JW; Sherrard DJ; Swan SK; Barrett JS; Assaid CA; Fossler MJ; Cox DS; Williams RM; Pittenger AL; Stephenson CA; Hua TA
Am J Kidney Dis; 2002 Sep; 40(3):531-8. PubMed ID: 12200805
[TBL] [Abstract][Full Text] [Related]
9. Low-molecular-weight heparin Fraxiparin in chronic hemodialysis. A dose-finding study.
Morinière P; Dieval J; Bayrou B; Roussel B; Renaud H; Fournier A; Delobel J
Blood Purif; 1989; 7(6):301-8. PubMed ID: 2558691
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the anticoagulant effect of low-molecular-weight heparins based on the anti-Xa level during haemodialysis.
Tao M; Zheng D; Liang X; Ye M; Liu Y; Li Y; Shen H; He Q
Nephrology (Carlton); 2020 Sep; 25(9):723-729. PubMed ID: 31999031
[TBL] [Abstract][Full Text] [Related]
11. Standard heparin versus low-molecular-weight heparin. A medium-term comparison in hemodialysis.
Stefoni S; Cianciolo G; Donati G; Colì L; La Manna G; Raimondi C; Dalmastri V; Orlandi V; D'Addio F
Nephron; 2002; 92(3):589-600. PubMed ID: 12372942
[TBL] [Abstract][Full Text] [Related]
12. Anticoagulant-free Genius haemodialysis using low molecular weight heparin-coated circuits.
Frank RD; Müller U; Lanzmich R; Groeger C; Floege J
Nephrol Dial Transplant; 2006 Apr; 21(4):1013-8. PubMed ID: 16326745
[TBL] [Abstract][Full Text] [Related]
13. Heparin-grafted dialysis membrane allows minimal systemic anticoagulation in regular hemodialysis patients: a prospective proof-of-concept study.
Kessler M; Gangemi C; Gutierrez Martones A; Lacombe JL; Krier-Coudert MJ; Galland R; Kielstein JT; Moureau F; Loughraieb N
Hemodial Int; 2013 Apr; 17(2):282-93. PubMed ID: 22925178
[TBL] [Abstract][Full Text] [Related]
14. Comparison between tinzaparin and standard heparin for chronic hemodialysis in a Canadian center.
Lord H; Jean N; Dumont M; Kassis J; Leblanc M
Am J Nephrol; 2002; 22(1):58-66. PubMed ID: 11919404
[TBL] [Abstract][Full Text] [Related]
15. Profile of low molecular weight tinzaparin sodium for anticoagulation during hemodialysis.
Al-Saran KA; Sabry A; Taha M; Ghafour MA; Al Fawzan F
Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):43-9. PubMed ID: 20061691
[TBL] [Abstract][Full Text] [Related]
16. Use of single dose low-molecular-weight heparin in long hemodialysis.
Lai KN; Ho K; Li M; Szeto CC
Int J Artif Organs; 1998 Apr; 21(4):196-200. PubMed ID: 9649059
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of coagulation and anti-Xa factor when using a heparin-coated AN69ST® dialyser.
Sánchez-Canel JJ; Pons-Prades R; Salvetti ML; Seores A; Vázquez M; Pérez-Alba A; Tamarit E; Calvo-Gordo C; Villatoro J
Nefrologia; 2012; 32(5):605-12. PubMed ID: 23013946
[TBL] [Abstract][Full Text] [Related]
18. Citrate compared to low molecular weight heparin anticoagulation in chronic hemodialysis patients.
Janssen MJ; Deegens JK; Kapinga TH; Beukhof JR; Huijgens PC; van Loenen AC; van der Meulen J
Kidney Int; 1996 Mar; 49(3):806-13. PubMed ID: 8648924
[TBL] [Abstract][Full Text] [Related]
19. Use of low-dose low molecular weight heparin in hemodialysis.
Lai KN; Wang AY; Ho K; Szeto CC; Li M; Wong LK; Yu AW
Am J Kidney Dis; 1996 Nov; 28(5):721-6. PubMed ID: 9158210
[TBL] [Abstract][Full Text] [Related]
20. [Prevention of thrombogenesis in the extracorporeal circuit of hemodialysis with a low molecular heparin: standardization of the dosage with a better hemorrhagic risk/effectiveness ratio].
Barata JD; Oliveira C; Bruges M; Gusmão L; Santana A; Ponce P; Simões J; Freire I; Crespo F; da Silva AN
Acta Med Port; 1992 Feb; 5(2):65-70. PubMed ID: 1317657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
